Physician

Manish Niranjan Trivedi, M.D.

According to 2025 Medicare claims, Manish Trivedi, M.D. (NPI: 1760785414) practices infectious disease in the Atlantic City-Hammonton, NJ market, with the plurality of this provider's patient population coming from Atlantic, NJ. This provider's primary affiliated billing organization is COASTAL INFECTIOUS DISEASE CONSULTANTS, LLC (NPI: 1023328945; TIN: 273051192) and primary practice location at 08205-9705.

Trivedi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,544 traditional Medicare patients, billed 7,407 HCPCS/CPT codes, and received $671,596 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 931 prescription claims across 113 beneficiaries totaling $135,066 in drug costs, led by Daptomycin (Daptomycin). 2023 DME data shows 26 claims. Open Payments data shows 31 records totaling $3,721. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $122,307 and ending at $135,066. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,257	42,948	$608,286
2016	1,326	59,118	$706,649
2017	1,597	149,408	$912,172
2018	1,716	91,067	$955,070
2019	1,639	157,530	$1,324,481
2020	1,466	26,765	$777,796
2021	1,482	8,232	$639,611
2022	1,352	7,655	$579,568
2023	1,542	7,949	$657,096
2024	1,544	7,407	$671,596

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	84	261	$122,307
2016	101	230	$76,550
2017	86	334	$200,382
2018	97	396	$146,475
2019	100	568	$272,552
2020	122	725	$239,386
2021	132	1,015	$193,364
2022	122	696	$206,020
2023	112	797	$150,060
2024	113	931	$135,066

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	22	$47,409
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	26	$60,542
2023	N/R	26	$62,322
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	65	65	$197
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	1,270	1,501	$116
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	972	2,126	$105
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	40	52	$83
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	797	3,618	$70

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Daptomycin	Daptomycin	167	1,063	$61,263
Ertapenem	Ertapenem Sodium	98	553	$33,262
Ceftriaxone	Ceftriaxone Sodium	246	1,642	$14,848
Piperacillin-Tazobactam	Piperacillin Sodium/Tazobactam	86	539	$6,628
Vancomycin Hcl	Vancomycin Hcl	25	157	$963

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	31	$3,721	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Manish Niranjan Trivedi, M.D.?

Tedicare shows public-source Medicare data for Manish Niranjan Trivedi, M.D. (NPI 1760785414), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Manish Niranjan Trivedi, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Manish Niranjan Trivedi, M.D.?

Manish Niranjan Trivedi, M.D. is linked to COASTAL INFECTIOUS DISEASE CONSULTANTS, LLC (billing NPI 1023328945) in the available physician profile data.

Does Manish Niranjan Trivedi, M.D. have Open Payments data?

Manish Niranjan Trivedi, M.D. has 31 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.